Skip to main content
  • Home
  • Heart Failure & Cardiomyopathy: Highlights 2019-2021

Heart Failure & Cardiomyopathy: Highlights 2019-2021

Topic:
  • CV Renal Metabolic
  • Heart Failure

Available Credit:

  • 0.25 AMA PRA Category 1 Credit™

Course Published On:

Course Expiry Date:

Overview

In this short CME-accredited programme, Prof Iacopo Olivotto provides a comprehensive look at the latest research and data presented at ACC 2021 impacting heart failure and hypertrophic cardiomyopathy.

Commercial Support

This activity is supported by an educational grant from Bristol Myers Squibb.

Method of Participation

This activity will take approximately 15 minutes to complete. To receive credit, participants are required to view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. There is no fee to participate in the activity or for the generation of the certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and Radcliffe Medical Education. ACHL is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.

Faculty Disclosures

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

 

The following financial relationships have been provided:

Advisory Board: Cytokinetics, MyoKardia

Grant(s): Cytokinetics, MyoKardia, Boston Scientific

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: N/A

Staff and Reviewer Disclosures

ACHL and Radcliffe Medical Education staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

 

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

 

This CME activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Target Audience

  • This activity is intended for cardiologists, heart failure specialists, and allied health professionals.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Recall the efficacy and safety of existing HCM treatments
  • Summarize results from ongoing trials with experimental treatments for HFrEF and HCM
Register now Log in

Speaker

lacopo Olivotto

Head of Cardiomyopathy Unit, Department of Experimental and Clinical Medicine, Division of General Cardiology, Careggi University Hospital (AOUC), Italy

View full profile

AVAILABLE CREDIT

0.25 AMA PRA Category 1 Credit™

Related Courses

Renal Denervation In The Real World: Practical Guidance For New Users
  • 1 EBAC

Learning objectives

  • Assess the current global burden of resistant hypertension
  • Carry out appropriate assessments to identify resistant hypertension
  • Identify patients most likely to benefit from RDN
  • Recall the practical considerations for adopting RDN into routine practice
  • Recall the latest data on RDN from recent clinical trials
See more
Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data.
  • Differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF).
  • Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF.
  • Assess the interrelationships linking diabetes, HF and CVD.
  • Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
  • Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
See more
Renal Denervation in Patients with Treatment-resistant Hypertension
  • 1.00 EBAC

Learning objectives

  • Describe the evidence to support the use of renal denervation as a treatment modality in patients with resistant hypertension
  • Understand renal denervation and how effective it is as a treatment option
  • Identify patients with resistant hypertension suitable for renal denervation
See more
Current and Emerging Data on SGLT2 Inhibitors in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data;
  • differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF);
  • apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF;
  • assess the interrelationships linking diabetes, HF and CVD;
  • interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF. Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
See more
Optimising Treatment of HF
  • 1.00 (EBAC)

Learning objectives

  • Recall recent changes to guidelines following the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes
  • Describe the type and extent of clinical benefit observed when SGLT2 inhibitors are added to standard HF therapy in patients with HFrEF
  • Assimilate prevailing hypotheses and insights from key thought leaders on optimal therapeutic sequencing of the ‘five pillars’ of HF therapy
  • Apply newly gained knowledge on therapeutic sequencing to surrogate patient cases
See more